| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Biofourmis | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Biolinq | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $275.18M | Series C-1 | 4/22/2025 | $100M | $397.31M | $1.05 | Alpha Wave Ventures, RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical, Features Capital | ||||
 | Cleerly | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $386.48M | Series C | 12/4/2024 | $330.08M | $729.01M | $11.78 | T. Rowe Price Associates, Fidelity Management, Sands Capital, Piper Sandler, Heartland Healthcare Capital funds, Mirae Asset Capital, Peter Thiel, Breyer Capital, Novartis, Pura Vida Investments, Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures, DigiTx Partners, Insight Partners, Battery Ventures | ||||
 | Cue Health | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $179.56M | Series C-1 | 6/10/2020 | $100M | $455.86M | $3.66 | Decheng Capital, Foresite Capital, Madrone Capital Partners, Johnson & Johnson Innovation, ACME Capital | ||||
 | Detect | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $77.02M | Series A-1 | 7/29/2026 | $31.99M | $118.22M | $1.22 | Undisclosed Investors | ||||
 | Element Science | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $115.4M | Series C-3 | 3/3/2020 | $163.35 | $296.95M | $1.63 | Deerfield Healthcare, Qiming Venture Partners, Cormorant Asset Management, Invus Opportunities, Third Rock Ventures, GV | ||||
 | Hazel Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $364.29M | Series E | 6/9/2026 | $99.03M | $396.96M | $2.40 | Undisclosed Investors | ||||
 | Human Longevity | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $91.95M | Series B-1 | 8/21/2024 | $32M | $185.79M | $0.31 | TVM Capital Healthcare, Panacea Venture, Emerging Technology Partners, Shin Ryoku Trust | ||||
 | Midi Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $251.97M | Series D | 2/3/2026 | $100M | $1B | $10.06 | Goodwater Capital, Foresite Capital, Serena Ventures, Advance Venture Partners, GV, Emerson Collective, SemperVirens, McKesson Ventures, Felicis | ||||
 | Nuna | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $117.69M | Series B-1 | 3/12/2020 | $26.74M | $492.55M | $34.05 | Undisclosed Investors | ||||
 | Nusano | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $474.68M | Series D-1 | 4/21/2026 | $180M | $655.01M | $1.25 | Undisclosed Investors | ||||
 | Owkin | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $279.77M | Series B-1 | 6/8/2022 | $50M | $1.46B | $45.70 | Bristol Myers Squibb | ||||
 | PathAI | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $255.49M | Series C | 5/19/2021 | $165M | $1.11B | $29.50 | D1 Capital Partners, Kaiser Permanente, General Atlantic, Tiger Global Management, 8VC, Adage, Biospring Partners, General Catalyst, KdT Ventures, Polaris Partners, Refactor Capital, Bristol-Myers Squibb Company, Labcorp, Merck Global Health Innovation Fund | ||||
 | SmarterDx | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $70.97M | Series B | 5/14/2024 | $50M | $341.85M | $16.75 | Transformation Capital, Bessemer Venture Partners, Flare Capital Partners, Floodgate | ||||
 | Suki | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $202.35M | Series E | 6/1/2026 | $40M | $443.36M | $5.99 | Undisclosed Investors | ||||
 | Two Chairs | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $92.39M | Series C | 4/16/2024 | $40M | $250.37M | $8.00 | Amplo, Fifth Down Capital | ||||
 | XtalPi | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | Affinia Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $219.17M | Series C | 10/7/2025 | $40M | $156.61M | $1.62 | New Enterprise Associates, Eli Lilly, Alexandria Venture Investments, Atlas Venture, Avidity Partners, F-Prime Capital, GV, Mass General Brigham Ventures, Perceptive Advisors | ||||
 | Alto Neuroscience | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $253.17M | Series C | 11/21/2023 | $50.31M | $235.65M | $4.71 | InVivium Capital, Franklin Templeton, Point72, Eli Lilly and Company, Alexandria Venture Investments, Alpha Wave Ventures, Lightswitch Capital, Alkeon Capital, WhatIf Ventures, Windham Venture Partners | ||||
 | Anumana | Healthcare Other Healthcare | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $185.3M | Series C | 4/24/2025 | $95.4M | $568.24M | $5.16 | Boston Scientific Corporation, Matrix Capital, Mayo Clinic, Matrix Partners, NTTVC | ||||
 | Carbon Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $688.42M | Super Series Senior-2 | 6/4/2025 | $20.2M | $485.04M | $1.71 | Undisclosed Investors | ||||
 | Cognito Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | ||||
 | DispatchHealth | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $315.45M | Series A-1 | 4/30/2026 | $61.99M | $444.87M | $63.16 | Undisclosed Investors | ||||
 | Firefly Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $240.86M | Series C | 10/25/2024 | $60M | $348.01M | $6.26 | Undisclosed Investors | ||||